^
    Back
    Association details:
    Biomarker:ALK F1174L
    Cancer:Neuroblastoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) +
    batoprotafib (TNO155) (PTPN11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Res Commun
    Title:

    SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma

    Published date:
    12/27/2023
    Excerpt:
    ...we show that lorlatinib-resistant ALK-F1174L neuroblastoma cells harbor additional RAS-MAPK pathway alterations and can be resensitized to lorlatinib when combined with TNO155 in vitro and in vivo.
    DOI:
    https://doi.org/10.1158/2767-9764.CRC-23-0234